Drug intelligence / Profile preview

North Star

Development stage: Phase 3
Lead developer: Accelas Pharmaceutical
Administration: Oral

Overview

North Star is an investigational desiccated thyroid extract (DTE) developed by Neuvosyn Laboratories, LLC, and Acella Pharmaceuticals for the treatment of primary hypothyroidism. It functions as a hormone replacement therapy, supplying both T4 (thyroxine) and T3 (triiodothyronine) to restore thyroid hormone levels. This aims to regulate metabolism, energy production, heart function, and brain health, offering an alternative to synthetic levothyroxine for patients who may not achieve full restoration with current treatments.

Other names: Desiccated Thyroid ExtractDTE

Targets

THR (Thyroid hormone receptor)

Beyond the preview

Go deeper on North Star.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on North Star.

Explore the full profile